Wolfe Research downgraded Verona Pharma (VRNA) to Peer Perform from Outperform without a price target after Merck (MRK) announced it will acquire Verona for $10B or $107 per share.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma downgraded to Neutral from Buy at Roth Capital
- Verona Pharma Stock (VRNA) Soars 20% on $10B Merck Deal
- Verona Pharma downgraded to Neutral from Buy at BTIG
- Verona Pharma downgraded to Equal Weight from Overweight at Wells Fargo
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!